- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Following the conclusion of the PinCell option and license arrangements, Scinai concentrates resources on its NanoAb platform and CDMO commercial execution, without taking on additional PC111 funding commitments JERUSALEM, Sept. 8, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative immunology therapeutic development with a revenue-generating contract development and manufacturing organization ("CDMO"), today announced a strategic refocusing of its R&D portfolio following the conclusion of its option and license arrangements with PinCell S.r.l. relating to PC111.Following discussions between Scinai and PinCell regarding a possible extension, no further agreement was reached. The applicable option conditions expired on August 31, 2026, and the Option Agreement and related License Agreement terminated in accordance with their terms. Scinai will now concentrate its R&D resources on its NanoAb platform while preserving capital and management capacity to support the continued growth and execution of Scinai Biopharma Services, its CDMO business. The outcome was not driven by any new negative scientific finding regarding PC111. Scinai continues to recognize the therapeutic potential of PC111 and appreciates the collaboration with the PinCell team. Amir Reichman, Chief Executive Officer of Scinai, commented: "PC111 remains an interesting and promising preclinical program, and we greatly appreciate our collaboration with Tony Amato and the PinCell team. Following the conclusion of our existing arrangements, our responsibility is to determine where Scinai's capital and management resources can create the greatest value for shareholders." "Advancing any preclinical asset through meaningful de-risking requires substantial capital and time. In the absence of secured grant funding for PC111, continuing our involvement would have required additional investment before there was visibility on non-dilutive financing. At the same time, we already have a multi-program NanoAb platform under our long-term research collaboration with the Max Planck Society and University Medical Center Göttingen as well as significant commercial opportunities emerging within our CDMO business." "We therefore believe concentrating our resources on these existing priorities is the appropriate capital-allocation decision for Scinai. It reduces prospective near-term R&D commitments while allowing us to focus on opportunities that we believe can create broader and more durable value for shareholders." Prioritizing a Platform with Multiple Development and Partnering Opportunities Scinai remains committed to its multi-year research collaboration with the Max Planck Society and University Medical Center Göttingen. The Company's NanoAb platform uses VHH antibody fragments to support the development of mono-, bi- and multi-specific therapeutic formats for inflammatory and immune-mediated di
Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT JERUSALEM, August 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (“Scinai” or the “Company”), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating contract development and manufacturing organization (“CDMO”), today provided a corporate update and reported financial results for the six months ended June 30, 2026. Corporate HighlightsCommitted Customer Orders1 reached approximately $3.1 million as of August 16, 2026, of which approximately $2.1 million had been invoiced.The Company is progressing an expanded clinical manufacturing and CMC program for a U.S.-based biopharmaceutical company building on an existing contractual relationship and prior work performed through the customer’s affiliate.Approximately $650 thousand in cash payments and advances have been received in connection with the expanded U.S. program, and substantive activities are underway while the definitive agreement covering the broader scope and commercial terms remains under negotiation.The expanded program is intended to support an investigational drug product toward U.S. IND submission and Phase III clinical development. First Half 2026 Financial ResultsRevenues increased to $949 thousand, compared with $773 thousand for the six months ended June 30, 2025. The increase was primarily attributable to the inclusion of revenues generated by the acquired Yavne operations from the acquisition date. Revenue recognized during the period reflects only the portion of customer engagements for which the applicable services had been performed and revenue recognition criteria satisfied through June 30, 2026, and does not reflect the full value of signed customer work orders extending beyond the reporting period.Cost of revenues increased to $3.3 million, compared to approximately $2.0 million for the six months ended June 30, 2025, primarily reflecting the expanded cost base of our CDMO business following the acquisition and consolidation of the Yavne operations, including additional personnel, facility, depreciation and other manufacturing-related costs.Gross loss was approximately $2.4 million, compared with approximately $1.3 million in the prior-year period, reflecting the expanded operating cost base of the Company’s CDMO platform while facility utilization continues to increase.Research and development expenses decreased to approximately $0.8 million, compared to approximately $1.2 million for the six months ended June 30, 2025 primarily reflecting a lower level of research and development expend
JERUSALEM, Aug. 10, 2026 /PRNewswire/ Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), has appointed Mr. Eran Kuratz as Head of Supply Chain and Business Process Administration. Mr. Kuratz reports directly to Scinai Chief Executive Officer Amir Reichman.Mr. Kuratz brings more than 30 years of senior leadership, supply chain and operational experience across the pharmaceutical, biotechnology, medical-device and industrial sectors. He has held senior positions at Kamada, Gamida Cell, OdysightAI, Elite PepsiCo-Frito-Lay and EnvyHer, including roles as CEO, Co-CEO, Director of Supply Chain and Director of Purchasing and Logistics. His experience spans global operations, procurement, logistics, warehousing, enterprise systems and strategic planning in highly regulated environments. Mr. Kuratz is a Practical Engineer in Industrial Engineering and Management from the Technological College of Be'er Sheva.In his new role, Mr. Kuratz leads Scinai Biopharma Services' supply chain and key operational support functions, including procurement and contracting, warehousing and inventory management, logistics, budgeting and cost control, bookkeeping administration, and IT and business systems. He is also responsible for enterprise platforms including ERP, CRM and quality-management systems, cybersecurity, and the continuous improvement of cross-functional business processes across the organization.Amir Reichman, Chief Executive Officer of Scinai, commented:"Following the expansion of our CDMO platform and the integration of our Jerusalem and Yavne operations, we are increasingly focused on building the systems, processes and organizational infrastructure required to operate effectively at a larger scale. Eran brings extensive experience in supply chain management, operational leadership and enterprise systems, and his appointment creates clear ownership for a number of critical cross-functional processes across the organization. We believe his experience will help us strengthen coordination between our sites and functions, improve operational discipline and establish scalable process
JERUSALEM, June 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended March 31, 2026 and provided a corporate update.Corporate HighlightsCompleted the acquisition of Recipharm Israel, expanding the Company's CDMO platform through the addition of a second manufacturing site in Yavne, Israel, and establishing a strategic commercial collaboration with global CDMO leader Recipharm AB.Advanced multiple non-dilutive funding initiatives supporting the Company's PC111 and NanoAb development programs.Prioritized development of a systemic IL-17 bispecific antibody as the lead validation program for the Company's NanoAb platform.Continued strategic collaboration activities with the Max Planck Society and University Medical Center Göttingen. Amir Reichman, Chief Executive Officer of Scinai, commented:"The first quarter of 2026 marked an important milestone in Scinai's evolution. Through the acquisition of Recipharm Israel and the subsequent consolidation of our CDMO activities under Scinai Biopharma Services, we have expanded our operational footprint, manufacturing capabilities and commercial reach. Scinai today consists of two complementary businesses: a focused immunology R&D organization advancing innovative therapeutic programs and Scinai Biopharma Services, our wholly owned CDMO subsidiary. We believe this structure provides multiple avenues for value creation, including CDMO growth, strategic partnerships, non-dilutive grant funding and advancement of innovative therapeutic programs.During the quarter, we strengthened our balance sheet through the Recipharm transaction, advanced multiple grant applications and refined our R&D strategy around programs that we believe offer the strongest scientific, commercial and partnering potential. As we move forward, our priorities remain clear: grow our CDMO business, secure non-dilutive funding, advance PC111 and our NanoAb platform, and continue building a capital-efficient biotechnology company capable of creating sustainable long-term shareholder value." Financial Results for the First Quarter of 2026Revenues for the three months ended March 31, 2026 were $489 thousand, compared to $586 thousand for the three months ended March 31, 2025. Revenue for the quarter included approximately $200 thousand generated by the Yavne facility following completion of the Recipharm Israel acquisition.Cost of revenues increased to $1.6 million from $0.4 million in the comparable prior-year period. The increase primarily reflected growth of the Company's CDMO operations
JERUSALEM, May 20, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), (“Scinai” or the “Company”), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), has appointed Mr. Eilon Elmalem as Site Head of its Yavne CDMO facility, effective June 14, 2026.Mr. Elmalem has worked with Scinai over the past two years as an external consultant and has supported the Company’s CDMO activities and operational development efforts. More recently, he has been involved in the transition and operational integration planning of the Yavne facility. In his new role, Mr. Elmalem will assume responsibility for site operations while continuing to oversee engineering activities, supporting the continued growth and operational development of Scinai’s CDMO platform. Mr. Elmalem brings more than 20 years of experience in engineering, operations, process development, and industrial infrastructure management within the biotechnology and pharmaceutical industries. Prior to joining Scinai, he held senior leadership roles at Merck, Sigma-Aldrich Millipore, including VP of Engineering and Process Development, where he oversaw engineering, manufacturing, R&D, and operational activities across multiple sites in Israel, Europe, and the United States. His experience includes management of multidisciplinary teams, execution of complex organizational transformation projects, establishment and expansion of GMP manufacturing facilities, and oversight of major capital investment programs.Amir Reichman, Chief Executive Officer of Scinai, commented: “We are pleased to welcome Eilon into this important leadership role. Over the past two years, Eilon has become an integral part of the growth and operational development of our CDMO platform. His extensive international operational experience, engineering expertise, and leadership capabilities will support the anticipated continued expansion, operational excellence, and long-term growth of our Yavne CDMO facility.”The transition and knowledge transfer process began on May 10, 2026, under the supervision of the current site head, Dr. Sylvia Kachalsky, who will continue to support the transition to ensure continuity of operations and effective transfer of responsibilities. Upon completion of the transition process, Dr. Kachalsky is expected to begin retirement leave prior to her planned retirement later in 2026.Mr. Reichman added: “I would also like to thank Sylvia for her leadership of the Yavne site over many years and for her important support throughout the transition and integration process following the acquisition from Recipharm. Her professionalism, operational expertise, and commitment have contributed significantly to the successful integration of the Yavne facility into Scinai Biopharma Services’ expanding CDMO platform and to the establishment of the commercial collaboration framework with Recipharm.”About Scinai ImmunotherapeuticsScinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies. The Company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l.Scinai also owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies.For more information
JERUSALEM, May 15, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company focused on inflammation and immunology, today announced that members of its leadership team will lead a strategic roundtable discussion at the 7th Dermatology Drug Development Summit Europe, taking place next week in Amsterdam, the Netherlands.The roundtable discussion, titled "Oral Therapies and the Future of Biologics: How Oral Peptides and Small Molecules Are Reshaping the Immunology Landscape", will be led by Amir Reichman, Chief Executive Officer of Scinai Immunotherapeutics, together with Dr. Meital Portugal, Director of R&D Operations.The discussion will focus on one of the emerging strategic questions in immunology and dermatology drug development: whether advances in oral peptide and small molecule therapies may complement biologics, reshape treatment sequencing, or meaningfully displace injectable therapies in selected disease settings.The session will explore scientific, clinical, commercial, and strategic questions currently facing the immunology industry, including: · Whether certain immunologic pathways may remain inherently more suitable for injectable biologics · Whether oral cytokine blockers can achieve biologic-competitive efficacy, selectivity, and long-term durability· Which diseases and cytokine pathways may be most vulnerable to oral therapeutic disruption· Whether the route of administration itself may become a strategic differentiator in immunology portfolio development· The evolving balance between efficacy, convenience, adherence, safety, persistence of response, and long-term disease control· How oral therapies may influence treatment sequencing, physician confidence, payer dynamics, and lifecycle management strategies for biologic franchisesThe roundtable will also examine key translational and clinical development challenges associated with oral immunology therapies, including pharmacokinetic variability, bioavailability limitations, treatment adherence dependence, durability of response, and sustained disease modification. "The immunology field is entering a period of rapid evolution where scientific innovation is no longer focused solely on efficacy, but increasingly also on durability, convenience, accessibility, treatment persistence, and strategic modality selection," said Amir Reichman, Chief Executive Officer of Scinai Immunotherapeutics. "One of the most important emerging questions for the industry is not simply whether oral therapies will grow, but rather where oral modalities may complement biologics, where they may compete directly, and which disease settings may continue to favour advanced biologic approaches. We believe these discussions are becoming increasingly important for companies developing next-generation immunology therapies." <p c
JERUSALEM, April 24, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics and the owner of Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), today announced that it has entered into a securities purchase agreement with an institutional life sciences investor, as well as with new and existing institutional and accredited investors, for the purchase and sale of 5,208,333 American Depositary Shares (ADSs), each representing 4,000 ordinary shares, at a purchase price of $0.48 per ADS, as well as a Series A warrant to purchase up to 5,208,333 ADSs at an exercise price of $0.48 per ADS, exercisable immediately with a term of two years, and a Series B warrant to purchase up to 5,208,333 ADSs at an exercise price of $0.55 per ADS, exercisable immediately with a term of five years.In addition, the Company entered into a warrant inducement agreement with an existing institutional investor of the Company for the immediate exercise of warrants to purchase up to 229,310 ADSs of its ordinary shares (the "Existing Warrants") at an exercise price of $0.48 per ADS.In consideration for the immediate exercise in full of the Existing Warrants for cash, the investor will receive in a private placement new unregistered warrants to purchase up to 458,621 ADSs (the "New Warrants"). The New Warrants will have an exercise price of $0.55 per ADS, will be exercisable immediately, and will expire five (5) years from the date of issuance.The aggregate gross proceeds from the private placement and the warrant inducement transaction are approximately $2.61 million, before deducting fees and expenses, and the closing of the transactions is expected to occur on or about April 27, 2026, subject to satisfaction of customary closing conditions.Scinai intends to use the net proceeds, together with existing cash resources, to support the expansion of its CDMO platform, advance customer programs, and continue selective investment in its immunotherapy pipeline. The Company believes this financing will support the execution of its growth strategy.A.G.P./Alliance Global Partners acted as the sole financial advisor for the transactions.The offer and sale of the foregoing securities will be made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Regulation D promulgated thereunder. Accordingly, the securities issued in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in this warrant inducement transaction, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any
JERUSALEM, April 6, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company developing inflammation and immunology therapeutics and operating a growing CDMO business, today announced the completion of a strategic corporate reorganization establishing a dedicated CDMO platform alongside a streamlined R&D organization.Building on its previously announced acquisition of Recipharm Israel Ltd. and related commercial collaboration with Recipharm, this reorganization represents a structural transformation of the Company's operating model, designed to enhance capital efficiency, improve operational focus and position each business to independently create and capture value.Formal Separation of CDMO and R&D ActivitiesFollowing the Company's previously announced acquisition of Recipharm Israel Ltd. in February 2026, which included a small-molecule drug development and manufacturing site in Yavne, the acquired entity was renamed Scinai Biopharma Services Ltd.As part of a corporate reorganization designed to consolidate CDMO activities, the Company transferred all CDMO-related operations, including employees, infrastructure, manufacturing facilities, customer contracts and associated business activities, into this entity, establishing Scinai Biopharma Services Ltd. as the Company's dedicated CDMO subsidiary. Scinai Biopharma Services now operates as a fully integrated, privately held CDMO platform, wholly owned by Scinai Immunotherapeutics. The reorganization was undertaken to position each part of the business more clearly for its respective stakeholders. This structure establishes a clear separation between:Scinai Biopharma Services – a dedicated, execution-focused CDMO business.Scinai Immunotherapeutics – a streamlined R&D organization focused on advancing innovative therapeutics.A Scalable CDMO Platform Built on Three Complementary PillarsThe Company's CDMO platform is built on three complementary pillars that together create a scalable and differentiated development and manufacturing offering. First, the Company's Jerusalem site provides biologics development, analytical services and aseptic manufacturing capabilities. Second, the acquisition of Recipharm Israel adds the Yavne site, expanding the platform into small-molecule development and API manufacturing, broadening the Company's technical scope and enabling access to a wider range of customer programs. Third, through its commercial collaboration with Recipharm, the Company has access to external manufacturing capabilities that function as a
JERUSALEM, April 1, 2026 /PRNewswire/- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model designed to combine therapeutic innovation with revenue-generating drug development and manufacturing services, today reported financial results for the year ended December 31, 2025. Corporate and Financial HighlightsCDMO revenues doubled year-over-year to $1.3 million, reflecting continued commercial traction and execution of development and manufacturing programs Expanded CDMO platform post year-end through the acquisition of Recipharm Israel and entry into a strategic commercial collaboration with Recipharm, enhancing manufacturing capabilities and broadening service offeringsEstablished a differentiated lifecycle CDMO model with global reach, enabling customer programs to transition from early-stage development through late-stage and commercial manufacturing Positioned PC111, a fully human monoclonal antibody targeting inflammatory pathways with potential applications in severe dermatological conditions, as the Company’s flagship value driver. Resubmitted application for non-dilutive FENG grant funding covering PC111 and IL-17-based programs, advancing key pipeline assets through capital-efficient funding mechanisms FENG grant structure provides significant capital efficiency, with €12 million of potential grant funding matched by approximately €3 million of Company investment, enabling up to 5x leverage on R&D capitalNet cash used in operating activities for the year ended December 31, 2025, was $6.0 million, representing a slight decrease year-over-year. Financial Results for Full-Year 2025Revenues for the year ended December 31, 2025, were $1.3 million, compared to $0.7 million for the year ended December 31, 2024. The increase reflects continued expansion of Scinai’s CDMO activities.R&D expenses for the year ended December 31, 2025, amounted to $2.4 million, compared to $5.5 million for the year ended December 31, 2024. The decrease was primarily due to lower allocation of employees and facility costs to the R&D business unit.Marketing, general and administrative expenses for the year ended December 31, 2025, were $2.5 million, compared to $2.5 million for the year ended December 31, 2024.Financial expenses, net, for the year ended December 31, 2025, were $0.8 million, compared to financial income of $13.4 million for the year ended December 31, 2024. The change was primarily d
JERUSALEM, March 19, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, and the owner of Scinai Biopharma Services Ltd., a rapidly expanding contract development and manufacturing organization (CDMO) serving biotechnology and pharmaceutical companies, today announced its participation in BIO-Europe Spring® 2026, taking place March 23–25 in Lisbon, Portugal. This will be Scinai's first major international conference following its recent acquisition of Recipharm Israel and strategic collaboration with Recipharm, marking a significant expansion of its development and manufacturing capabilities. The Scinai delegation will include: Amir Reichman, Chief Executive Officer, representing Scinai Immunotherapeutics' R&D activitiesSolomon Gahtan, Business Development & Alliance Management, BiologicsDr. Helen Domeshek, Business Development & Alliance Management, Small Molecules Mr. Gahtan and Dr. Domeshek will represent Scinai Biopharma Services Ltd., the Company's CDMO subsidiary. During the conference, the team will meet with pharmaceutical and biotechnology companies, investors, and prospective clients to advance both Scinai's innovative R&D pipeline and its integrated CDMO offering. Expanding a Differentiated Integrated CDMO Platform from Early Development to Commercial Supply Through Scinai Biopharma Services Ltd., the Company offers a differentiated, integrated CDMO platform supporting biotechnology and pharmaceutical companies from early development through commercialization. Scinai's model is built on three strategic pillars: a cGMP biologics development and manufacturing site in Jerusalem, a cGMP small-molecule API development and manufacturing site in Yavne acquired from Recipharm, and a strategic commercial collaboration with Recipharm. This structure positions Scinai as a unique partner bridging early-stage innovation with global commercial manufacturing. The Recipharm collaboration expands Scinai's capabilities through access to additional capacity and technologies via subcontracting, enables a seamless client "graduation" model from preclinical and clinical development to late-stage and commercial production, and aligns quality and tech transfer standards to significantly reduce execution risk and accelerate timelines.</p
